ERBB2

Across TCGA pan-cancer cohorts, ERBB2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ERBB2 data layer compared with 24 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ERBB2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ERBB2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, GBM, and LUAD are the cancer types where ERBB2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	All	0.940	0.655	.001	63	view →
GBM	DFS	Median	All	0.270	0.466	<.001	21	view →
LUAD	OS	Median	III,IV	0.800	0.352	.004	17	view →
OV	DFS	Median	All	0.656	1.000	.013	8	view →
HNSC	OS	Median	All	0.942	0.991	.026	3	view →
LSCC	OS	Tertile	All	0.666	0.885	.035	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ERBB2–CCRCC (OS)

Open the CCRCC breakdown →